CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider William Michael Kavanaugh sold 48,368 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total transaction of $1,177,277.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down 2.54% during midday trading on Friday, hitting $21.50. 215,136 shares of the stock were exchanged. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $24.67. The company’s market cap is $792.64 million. The firm has a 50-day moving average price of $17.15 and a 200-day moving average price of $15.67.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. On average, equities analysts predict that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current year.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/06/cytomx-therapeutics-inc-ctmx-insider-william-michael-kavanaugh-sells-48368-shares.html.

CTMX has been the subject of a number of research reports. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Nomura boosted their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America Corporation reissued a “buy” rating and issued a $30.00 price target (up from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Finally, ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.67.

Several institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC bought a new stake in CytomX Therapeutics in the 1st quarter valued at about $13,729,000. Numeric Investors LLC bought a new stake in CytomX Therapeutics in the 2nd quarter valued at about $9,730,000. Perceptive Advisors LLC lifted its position in CytomX Therapeutics by 65.7% in the 1st quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock valued at $26,434,000 after purchasing an additional 606,896 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in CytomX Therapeutics in the 1st quarter valued at about $5,089,000. Finally, State Street Corp lifted its position in CytomX Therapeutics by 58.8% in the 2nd quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after purchasing an additional 165,342 shares during the last quarter. Institutional investors own 59.97% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.